The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis

Multiple Sclerosis and Related Disorders

Volumn 1, Issue 2, 2012, Pages 64-75

  Baker, David ^a   Pryce, Gareth ^a   Jackson, Samuel J ^a   Bolton, Chris ^a   Giovannoni, Gavin ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cannabis; Endocannabinnoid; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Neuroprotection; Spasticity

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 AMINOBUTYRIC ACID B RECEPTOR; ABC TRANSPORTER G1; ANANDAMIDE; BACLOFEN; CANNABIDIOL; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID RECEPTOR; CANNABIS; DANTROLENE; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; ION CHANNEL; MULTIDRUG RESISTANCE PROTEIN 1; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABIXIMOLS; POTASSIUM; RIMONABANT; TETRAHYDROCANNABINOL; VANILLOID RECEPTOR 1;

ALLERGIC ENCEPHALOMYELITIS; BINDING AFFINITY; BLOOD BRAIN BARRIER; CELL INFILTRATION; CHANNEL GATING; DEMYELINATION; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG PENETRATION; DRUG TARGETING; ENZYME INHIBITION; EXCITATION CONTRACTION COUPLING; HUMAN; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NERVE INJURY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL DISABILITY; POTASSIUM CONDUCTANCE; PYRAMIDAL TRACT; RECEPTOR BINDING; RECEPTOR UPREGULATION; REVIEW; SEDATION; SIDE EFFECT; SPASTICITY;

EID: 84857791339     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2011.11.001     Document Type: Review

References (178)

1. M.M. Adams, and A.L. Hicks Spasticity after spinal cord injury Spinal Cord 43 2005 577 586 (Pubitemid 41486865)
2. N. Agarwal, P. Pacher, and I. Tegeder Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors Nature Neuroscience 10 2007 870 879 (Pubitemid 47013432)
3. S. Al-Izki, G. Pryce, S.J. Jackson, G. Giovannoni, and D. Baker Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis Multiple Sclerosis 17 2011 939 948
4. S. Al-Izki, G. Pryce, G. Giovannoni, and D. Baker Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography Multiple Sclerosis 15 2009 795 801
5. K. Ahn, S.E. Smith, M.B. Liimatta, D. Beidler, N. Sadagopan, and D.T. Dudley Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain Journal of Pharmacology and Experimental Therapeutics 338 2011 114 124
6. M. Aragona, E. Onesti, V. Tomassini, A. Conte, S. Gupta, and F. Gilio Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study Clinical Neuropharmacology 32 2009 41 47
7. A. Arévalo-Martín, J.M. Vela, E. Molina-Holgado, J. Borrell, and C. Guaza Therapeutic action of cannabinoids in a murine model of multiple sclerosis Journal of Neuroscience 23 2003 2511 2516 (Pubitemid 36418583)
8. D. Baker, W. Gerritsen, J. Rundle, and S. Amor Critical appraisal of animal models of multiple sclerosis Multiple Sclerosis 17 2011 647 657
9. D. Baker, and S.J. Jackson Models of multiple sclerosis Advances in Clinical Neuroscience and Rehabilitation 6 2007 10 12
10. D. Baker, J.K. ONeill, C. Wilcox, S. Gschmeissner, C. Butter, and J.L. Turk Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice Journal of Neuroimmunology 28 1990 261 270 (Pubitemid 20207821)
11. D. Baker, G. Pryce, J.L. Croxford, P. Brown, R.G. Pertwee, and J.W. Huffman Cannabinoids control spasticity and tremor in a multiple sclerosis model Nature 404 2000 84 87 (Pubitemid 30143137)
12. D. Baker, G. Pryce, J.L. Croxford, P. Brown, R.G. Pertwee, and A. Makriyannis Endocannabinoids control spasticity in a multiple sclerosis model FASEB Journal 15 2001 300 302
13. Baker D, Pryce G, Giovannoni G, Thompson AJ. Methods for treatment of inflammatory diseases using CT-3 or analogs thereof WO; 2004, 100893.
14. M. Barann, G. Molderings, M. Bruss, H. Bonisch, B.W. Urban, and M. Gothert Direct inhibition by cannabinoids of human 5-HT(3 A) receptors: probable involvement of an allosteric modulatory site British Journal of Pharmacology 137 2002 589 596 (Pubitemid 35333084)
15. B.S. Basavarajappa Critical enzymes involved in endocannabinoid metabolism Protein & Peptide Letters 14 2007 237 246 (Pubitemid 46376854)
16. M. Beltramo, N. Stella, A. Calignano, S.Y. Lin, A. Makriyannis, and D. Piomelli Functional role of high-affinity anandamide transport, as revealed by selective inhibition Science 277 1094 1997 1097
17. P. Berghuis, A.M. Rajnicek, Y.M. Morozov, R.A. Ross, J. Mulder, and G.M. Urbán Hardwiring the brain: endocannabinoids shape neuronal connectivity Science 316 2007 1212 1216 (Pubitemid 46880959)
18. G93A mouse model of ALS FASEB Journal 20 2006 1003 1005
19. S. Bittner, S.G. Meuth, K. Göbel, N. Melzer, A.M. Herrmann, and O.J. Simon TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system Brain 132 2009 2501 2516
20. J.L. Blankman, G.M. Simon, and B.F. Cravatt A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol Chemistry & Biology 14 2007 1347 1356 (Pubitemid 350257008)
21. D.L. Boger, H. Sato, A.E. Lerner, M.P. Hedrick, R.A. Fecik, and H. Miyauchi Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide Proceedings of the National Academy of Sciences, United States of America 97 2000 5044 5049 (Pubitemid 30313668)
22. L. Bonhomme-Faivre, A. Benyamina, M. Reynaud, R. Farinotti, and C. Abbara Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein Addiction Biology 13 2008 295 300
23. L.M. Bornheim, K.Y. Kim, J. Li, B.Y. Perotti, and L.Z. Benet Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain Drug Metabolism and Disposition 23 1995 825 831
24. J.W. Brooks, G. Pryce, and T. Bisogno Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors European Journal of Pharmacology 439 2002 83 92 (Pubitemid 34286610)
25. P. Brown Pathophysiology of spasticity Journal of Neurology, Neurosurgery & Psychiatry 57 1994 773 777 (Pubitemid 24214953)
26. CAMMS223 Trial Investigators, A.J. Coles, D.A. Compston, K.W. Selmaj, S.L. Lake, and S. Moran Alemtuzumab vs. interferon beta-1a in early multiple sclerosis New England Journal of Medicine 359 2008 1786 1801
27. A. Cabranes, K. Venderova, and E. de Lago Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis Neurobiology of Disease 20 2005 207 217 (Pubitemid 41476248)
28. V. Chevaleyre, K.A. Takahashi, and P.E. Castillo Endocannabinoid-mediated synaptic plasticity in the CNS Annual Review of Neuroscience 29 2006 37 76 (Pubitemid 44476839)
29. A.J. Clark, M.A. Ware, E. Yazer, T.J. Murray, and M.E. Lynch Patterns of cannabis use among patients with multiple sclerosis Neurology 62 2004 2098 2100 (Pubitemid 38738230)
30. A.J. Coles, M.G. Wing, P. Molyneux, A. Paolillo, C.M. Davie, and G. Hale Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis Annals of Neurology 46 1999 296 304 (Pubitemid 29416266)
31. C. Collin, P. Davies, I.K. Mutiboko, S. Ratcliffe Sativex Spasticity in MS Study Group Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis European Journal of Neurology 14 2007 290 296 (Pubitemid 46384865)
32. F. Comelli, G. Giagnoni, I. Bettoni, M. Colleoni, and B. Costa The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation British Journal of Pharmacology 152 2007 787 794 (Pubitemid 350034978)
33. D. Centonze, M. Bari, S. Rossi, C. Prosperetti, R. Furlan, and F. Fezza The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis Brain 130 2007 2543 2553 (Pubitemid 47511703)
34. D. Centonze, F. Mori, G. Koch, F. Buttari, C. Codecà, and S. Rossi Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis Neurological Sciences 30 2009 531 534
35. C. Collin, E. Ehler, G. Waberzinek, Z. Alsindi, P. Davies, and K. Powell A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis Neurological Research 32 2010 451 459
36. A. Compston, and A. Coles Multiple sclerosis Lancet 359 2002 1221 1231 (Pubitemid 34304266)
37. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
38. P. Consroe, R. Musty, J. Rein, W. Tillery, and R. Pertwee The perceived effects of smoked cannabis on patients with multiple sclerosis European Neurology 38 1997 44 48 (Pubitemid 27283078)
39. A. Conte, C.M. Bettolo, E. Onesti, V. Frasca, E. Iacovelli, and F. Gilio Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis European Journal of Pain 13 2009 472 477
40. B.F. Cravatt, and A.H. Lichtman The enzymatic inactivation of the fatty acid amide class of signaling lipids Chemistry and Physics of Lipids 121 2002 135 148 (Pubitemid 36044548)
41. J.L. Croxford, G. Pryce, S.J. Jackson, C. Ledent, G. Giovannoni, and R.G. Pertweee Cannabinoid-mediated neuroprotection, not immunosuppression, may be relevant to multiple sclerosis Journal of Neuroimmunology 193 2008 120 129
42. E. de Lago, J. Fernández-Ruiz, S. Ortega-Gutiérrez, A. Cabranes, G. Pryce, and D. Baker UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntingtons disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders European Neuropsychopharmacology 16 2006 7 18 (Pubitemid 43005091)
43. E. de Lago, A. Ligresti, G. Ortar, E. Morera, A. Cabranes, and G. Pryce In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake European Journal of Pharmacology 484 2004 249 257 (Pubitemid 38117217)
44. D.G. Deutsch, N. Ueda, and S. Yamamoto The fatty acid amide hydrolase (FAAH) Prostaglandins, Leukotrienes and Essential Fatty Acids 66 2002 201 210 (Pubitemid 34743595)
45. W.A. Devane, F.A. Dysarz, M.R. Johnson, L.S. Melvin, and A.C. Howlett Determination and characterization of a cannabinoid receptor in rat brain Molecular Pharmacology 34 1988 605 613 (Pubitemid 19007296)
46. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, and G. Griffin Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949 (Pubitemid 23026736)
47. M.A. Diana, and A. Marty Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE) British Journal of Pharmacology 142 2004 9 19 (Pubitemid 38698187)
48. T.P. Dinh, T.F. Freund, and D. Piomelli A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation Chemistry and Physics of Lipids 121 2002 149 158 (Pubitemid 36044549)
49. V. Di Marzo Endocannabinoids: synthesis and degradation Reviews of Physiology, Biochemistry and Pharmacology 160 2008 1 24
50. V. Di Marzo, and M. Maccarrone FAAH and anandamide: is 2-AG really the odd one out? Trends in Pharmacological Sciences 29 2008 229 233
51. E. Di Pasquale, H. Chahinian, P. Sanchez, and J. Fantini The insertion and transport of anandamide in synthetic lipid membranes are both cholesterol-dependent PLoS One 4 2009 e4989
52. F. Docagne, V. Muñetón, D. Clemente, C. Ali, F. Loría, and F. Correa Excitotoxicity in a chronic model of multiple sclerosis: neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation Molecular and Cellular Neuroscience 34 2007 551 561 (Pubitemid 46483078)
53. G.M. Drew, V.A. Mitchell, and C.W. Vaughan Glutamate spillover modulates GABAergic synaptic transmission in the rat midbrain periaqueductal grey via metabotropic glutamate receptors and endocannabinoid signaling Journal of Neuroscience 28 2008 808 815 (Pubitemid 351158994)
54. R. Dutta, J. McDonough, X. Yin, J. Peterson, A. Chang, and T. Torres Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients Annals of Neurology 59 2006 478 489 (Pubitemid 43358068)
55. R. Dutta, and B.D. Trapp Pathogenesis of axonal and neuronal damage in multiple sclerosis Neurology 68 3 2007 S22 S31
56. E.K. Dziadulewicz, S.J. Bevan, C.T. Brain, P.R. Coote, A.J. Culshaw, and A.J. Davis Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration Journal of Medicinal Chemistry 50 2007 3851 3856 (Pubitemid 47292048)
57. A. Dyson, M. Peacock, A. Chen, J.P. Courade, M. Yaqoob, and A. Groarke Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat Pain 116 2005 129 137 (Pubitemid 40828508)
58. E. Eljaschewitsch, A. Witting, C. Mawrin, T. Lee, P.M. Schmidt, and S. Wolf The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells Neuron 49 2006 67 79 (Pubitemid 43017186)
59. A.B. El-Remessy, I.E. Khalil, S. Matragoon, G. Abou-Mohamed, N.J. Tsai, and P. Roon Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite American Journal of Pathology 163 2003 1997 2008 (Pubitemid 37310030)
60. A. Franklin, and N. Stella Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol- sensitive receptors European Journal of Pharmacology 474 2003 195 198 (Pubitemid 37281448)
61. R.M. Freeman, O. Adekanmi, M.R. Waterfield, A.E. Waterfield, D. Wright, and J. Zajicek The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS) International Urogynecology Journal and Pelvic Floor Dysfunction 17 2006 636 641 (Pubitemid 44575283)
62. Fu J, Bottegoni G, Sasso O, Bertorelli R, Rocchia W, Masetti M, et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nature Neuroscience 2011 (November 20). doi:10.1038/nn.2986 [Epub].
63. Y. Gao, D.V. Vasilyev, M.B. Goncalves, F.V. Howell, C. Hobbs, and M. Reisenberg Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice Journal of Neuroscience 30 2010 2017 2024
64. G. Giovannoni, G. Comi, S. Cook, K. Rammohan, P. Rieckmann, and P. Soelberg Sørensen A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis New England Journal of Medicine 362 2010 416 426
65. S.T. Glaser, N.A. Abumrad, F. Fatade, M. Kaczocha, K.M. Studholme, and D.G. Deutsch Evidence against the presence of an anandamide transporter Proceedings of the National Academy of Sciences of the United States of America 100 2003 4269 4274 (Pubitemid 36418192)
66. J. Guo, and S.R. Ikeda Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons Molecular Pharmacology 65 2004 665 674 (Pubitemid 38264034)
67. A.J. Hampson, M. Grimaldi, J. Axelrod, and D. Wink Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants Proceedings of the National Academy of Sciences of the United States of America 95 1998 8268 8273 (Pubitemid 28326102)
68. D.W. Hampton, J. Anderson, G. Pryce, K.A. Irvine, G. Giovannoni, and J.W. Fawcett An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss Journal of Neuroimmunology 201202 2008 200 211
69. Y. Hashimotodani, T. Ohno-Shosaku, T. Maejima, K. Fukami, and M. Kano Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release Neuropharmacology 54 2008 58 67 (Pubitemid 350299399)
70. H. Hasseldam, and F.F. Johansen Neuroprotection without immunomodulation is not sufficient to reduce first relapse severity in experimental autoimmune encephalomyelitis Neuroimmunomodulation 17 2010 252 264
71. H. Hasseldam, and F.F. Johansen Cannabinoid treatment renders neurons less vulnerable than oligodendrocytes in experimental autoimmune encephalomyelitis International Journal of Neuroscience 2011 [Epub Jun 15]
72. K. Hayakawa, K. Mishima, M. Hazekawa, K. Sano, K. Irie, and K. Orito Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism Brain Research 1188 2008 157 164 (Pubitemid 350296050)
73. K. Hayakawa, K. Mishima, M. Nozako, M. Hazekawa, K. Irie, and M. Fujioka Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism Journal of Neurochemistry 102 2007 1488 1496 (Pubitemid 47256190)
74. M. Herkenham, A.B. Lynn, M.D. Little, M.R. Johnson, L.S. Melvin, and B.R. de Costa Cannabinoid receptor localization in brain Proceedings of the National Academy of Sciences of the United States of America 87 1990 1932 1936
75. A. Hermann, M. Kaczocha, and D.G. Deutsch 2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook AAPS Journal 8 2006 E409 E412
76. M.L. Holland, D.T. Lau, J.D. Allen, and J.C. Arnold The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids British Journal of Pharmacology 152 2007 815 824 (Pubitemid 350034987)
77. M.L. Holland, J.D. Allen, and J.C. Arnold Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1) European Journal of Pharmacology 591 2008 128 131
78. L.E. Hollister, and H. Gillespie Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol Clinical Pharmacology & Therapeutics 18 1975 80 83
79. K. Honarmand, M.C. Tierney, P. OConnor, and A. Feinstein Effects of cannabis on cognitive function in patients with multiple sclerosis Neurology 76 2011 1153 1160
80. A.C. Howlett Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes Molecular Pharmacology 27 1985 429 436 (Pubitemid 15088930)
81. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, and W.A. Devane International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacological Reviews 54 2002 161 202 (Pubitemid 34575709)
82. A.C. Howlett, P.H. Reggio, S.R. Childers, R.E. Hampson, N.M. Ulloa, and D.G. Deutsch Endocannabinoid tone versus constitutive activity of cannabinoid receptors British Journal of Pharmacology 163 2011 1329 1343
83. M.A. Huestis, S.J. Boyd, S.J. Heishman, K.L. Preston, D. Bonnet, and G. Le Fur Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users Psychopharmacology 194 2007 505 515 (Pubitemid 47492992)
84. M.A. Huestis, D.A. Gorelick, S.J. Heishman, K.L. Preston, R.A. Nelson, and E.T. Moolchan Blockade of effects of smoked marijuana by the CB1-selective c annabinoid receptor antagonist SR141716 Archives of General Psychiatry 58 2001 322 328 (Pubitemid 32299527)
85. M. Iskedjian, B. Bereza, A. Gordon, C. Piwko, and T.R. Einarson Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain Current Medical Research and Opinion 23 2007 17 24 (Pubitemid 46191666)
86. A.A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo, and R. Mechoulam Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb Trends in Pharmacological Sciences 30 2009 515 527
87. S.L. Jackson, G. Pryce, D.T. Diemel, and D. Baker Cannabinoid receptor null mice are susceptible to neurofilament damage and caspase 3 activation Neuroscience 134 2005 261 268 (Pubitemid 40943652)
88. A. Jarrahian, S. Manna, W.S. Edgemond, W.B. Campbell, and C.J. Hillard Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter Journal of Neurochemistry 74 2000 2597 2606 (Pubitemid 30314238)
89. A. Jayamanne, R. Greenwood, V.A. Mitchell, S. Aslan, D. Piomelli, and C.W. Vaughan Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models British Journal of Pharmacology 147 2006 281 288 (Pubitemid 43214685)
90. K.M. Jung, G. Astarita, C. Zhu, M. Wallace, K. Mackie, and D. Piomelli A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization Molecular Pharmacology 72 2007 612 621 (Pubitemid 47347296)
91. E.L. Karschner, W.D. Darwin, R.S. Goodwin, S. Wright, and M.A. Huestis Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration Clinical Chemistry 57 2011 66 75
92. I. Katona, and T.F. Freund Endocannabinoid signaling as a synaptic circuit breaker in neurological disease Nature Medicine 14 2008 923 930
93. S. Katona, E. Kaminski, H. Sanders, and J. Zajicek Cannabinoid influence on cytokine profile in multiple sclerosis Clinical and Experimental Immunology 140 2005 580 585 (Pubitemid 40813971)
94. R.B. Kavia, D. De Ridder, C.S. Constantinescu, C.G. Stott, and C.J. Fowler Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis Multiple Sclerosis 16 2010 1349 1359
95. J. Killestein, E.L. Hoogervorst, M. Reif, B. Blauw, M. Smits, and B.M. Uitdehaag Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis Journal of Neuroimmunology 137 2003 140 143 (Pubitemid 36351576)
96. K. Kim, D.H. Moore, A. Makriyannis, and M.E. Abood AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis European Journal of Pharmacology 542 2006 100 105 (Pubitemid 44096919)
97. A Klegeris, CJ Bissonnette, and PL. McGeer Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor British Journal of Pharmacology 139 2003 775 786 (Pubitemid 36819605)
98. Z. Kmietowicz Cannabis based drug is licensed for spasticity in patients with MS British Medical Journal 340 2010 c3363
99. G. Kooij, J. van Horssen, E.C. de Lange, A. Reijerkerk, S.M. van der Pol, and B. van Het Hof T lymphocytes impair P-glycoprotein function during neuroinflammation Journal of Autoimmunity 34 2010 416 425
100. E. Kozela, N. Lev, N. Kaushansky, R. Eilam, N. Rimmerman, and R. Levy Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice British Journal of Pharmacology 163 2011 1507 1519
101. A.C. Kreitzer, and W.G. Regehr Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells Neuron 29 2001 717 727 (Pubitemid 32323944)
102. D. Leung, A. Saghatelian, G.M. Simon, and B.F. Cravatt Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids Biochemistry 45 2006 4720 4726
103. A.H. Lichtman, E.G. Hawkins, G. Griffin, and B.F. Cravatt Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo Journal of Pharmacology and Experimental Therapeutics 302 2002 73 79 (Pubitemid 34680423)
104. A. Ligresti, M.G. Cascio, G. Pryce, S. Kulasegram, I. Beletskaya, and L. De Petrocellis New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis British Journal of Pharmacology 147 2006 83 91 (Pubitemid 43069099)
105. J. Liu, L. Wang, and J. Harvey-White Multiple pathways involved in the biosynthesis of anandamide Neuropharmacology 54 2008 1 7 (Pubitemid 350299395)
106. J.Z. Long, W. Li, L. Booker, J.J. Burston, S.G. Kinsey, and J.E. Schlosburg Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nature Chemical Biology 5 2009 37 44
107. F. Loría, S. Petrosino, M. Hernangómez, L. Mestre, A. Spagnolo, and F. Correa An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis Neurobiology of Disease 37 2010 166 176
108. A. Lourbopoulos, N. Grigoriadis, R. Lagoudaki, O. Touloumi, E. Polyzoidou, and I. Mavromatis Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis Brain Research 1390 2011 126 141
109. A. Ludányi, S.S. Hu, M. Yamazaki, A. Tanimura, D. Piomelli, and M. Watanabe Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus Neuroscience 174 2011 50 63
110. W.D. Lyman, J.R. Sonett, C.F. Brosnan, R. Elkin, and M.B. Bornstein Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis Journal of Neuroimmunology 23 1989 73 81 (Pubitemid 19125801)
111. M. Maccarrone, S. Rossi, and M. Bari Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum Nature Neuroscience 11 2008 152 159 (Pubitemid 351170502)
112. T. Maejima, K. Hashimoto, T. Yoshida, A. Aiba, and M. Kano Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors Neuron 31 2001 463 475 (Pubitemid 32778564)
113. 2 on autoreactive T Cells Nature Medicine 13 2007 492 497 (Pubitemid 46559830)
114. W.R. Marrs, J.L. Blankman, E.A. Horne, A. Thomazeau, Y.H. Lin, and J. Coy The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors Nature Neuroscience 13 2010 951 957
115. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
116. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, and A.R. Schatz Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochemical Pharmacology 50 1995 83 90
117. R. Mechoulam, and Y. Gaoni The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish Tetrahedron Letters 12 1967 1109 1111
118. L. Mestre, F. Docagne, F. Correa, F. Loría, M. Hernangómez, and J. Borrell A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules Molecular and Cellular Neuroscience 40 2009 258 266
119. T. Nagayama, A.D. Sinor, R.P. Simon, J. Chen, S.H. Graham, and K. Jin Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures Journal of Neuroscience 19 1999 2987 2995 (Pubitemid 29173995)
120. J.B. Nielsen, C. Crone, and H. Hultborn The spinal pathophysiology of spasticity - from a basic science point of view Acta Physiologica 189 2007 171 180 (Pubitemid 46148327)
121. W. Notcutt, R. Langford, P. Davies, S. Ratcliffe, and R. Potts A placebo-controlled, parallel-group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols) Multiple Sclerosis 2011 [Epub Aug 30]
122. ®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis European Journal of Neurology 18 2011 1122 1131
123. R. Nyilas, B. Dudok, and G.M. Urbán Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals Journal of Neuroscience 28 2008 1058 1063 (Pubitemid 351186335)
124. M. Oshiro, M.P. Hefferan, O. Kakinohana, N. Lukacova, K. Sugahara, and T.L. Yaksh Suppression of stretch reflex activity after spinal or systemic treatment with AMPA receptor antagonist NGX424 in rats with developed baclofen tolerance British Journal of Pharmacology 161 2010 976 985
125. M.J. Oudin, S. Gajendra, G. Williams, C. Hobbs, G. Lalli, and P. Doherty Endocannabinoids regulate the migration of subventricular zone-derived neuroblasts in the postnatal brain Journal of Neuroscience 31 2011 4000 4011
126. J. Palazuelos, N. Davoust, B. Julien, E. Hatterer, T. Aguado, and R. Mechoulam The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis Journal of Biological Chemistry 283 2008 13320 13329
127. B. Pan, W. Wang, J. Long, D. Sun, C.J. Hillard, and B.F. Cravatt Blockade of 2-AG hydrolysis by selective monoacylglycerol lipase inhibitor JZL184 enhances retrograde endocannabinoid signaling Journal Of Pharmacology and Experimental Therapeutics 2009 [Epub]
128. D. Panikashvili, C. Simeonidou, S. Ben-Shabat, L. Hanus, A. Breuer, and R. Mechoulam An endogenous cannabinoid (2-AG) is neuroprotective after brain injury Nature 413 2001 527 531 (Pubitemid 32938751)
129. S Parmentier-Batteur, K Jin, XO Mao, L Xie, and DA. Greenberg Increased severity of stroke in CB1 cannabinoid receptor knock-out mice Journal of Neuroscience 22 2002 9771 9775 (Pubitemid 35332860)
130. ® (THC:CBD) on the inhibition of spasticity in an experimental model of multiple sclerosis Multiple Sclerosis 16 2010 S234
131. S. Patel, E.J. Carrier, W.S. Ho, D.J. Rademacher, S. Cunningham, and D.S. Reddy The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity Journal of Lipid Research 46 2005 342 349 (Pubitemid 40271098)
132. R.G. Pertwee Pharmacology of cannabinoid receptor ligands Current Medicinal Chemistry 6 1999 635 664 (Pubitemid 29399497)
133. R.G. Pertwee The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9- tetrahydrocannabivarin British Journal of Pharmacology 153 2008 199 215
134. 2 Pharmacological Reviews 62 2010 588 631
135. C.H. Polman, P.W. OConnor, E. Havrdova, M. Hutchinson, L. Kappos, and D.H. Miller A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis New England Journal of Medicine 354 2006 899 910
136. G. Pryce, Z. Ahmed, D.J. Hankey, S.J. Jackson, J.L. Croxford, and J.M. Pocock Cannabinoids inhibit neurodegeneration in models of multiple sclerosis Brain 126 2003 2191 2202 (Pubitemid 37432364)
137. 2, cannabinoid receptor mediated British Journal of Pharmacology 150 2007 519 525 (Pubitemid 46280648)
138. G. Pryce, J.K.A. O'Neill, J.L. Croxford, S. Amor, D.R.J. Hankey, and G.
139. G.S. Rachelefsky, G. Opelz, M.R. Mickey, P. Lessin, M. Kiuchi, and M.J. Silverstein Intact humoral and cell-mediated immunity in chronic marijuana smoking Journal of Allergy and Clinical Immunology 58 1976 483 490
140. V. Ralevic, D.A. Kendall, J.C. Jerman, D.N. Middlemiss, and D. Smart Cannabinoid activation of recombinant and endogenous vanilloid receptors European Journal of Pharmacology 424 2001 211 219 (Pubitemid 32728310)
141. R.M. Ransohoff EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis Trends in Immunology 27 2006 167 168
142. G.P. Rice, M. Filippi, and G. Comi Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group Neurology 54 2000 1145 1155 (Pubitemid 30151860)
143. P. Robson Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine Expert Opinion on Drug Safety 2011 [Epub. May 4]
144. D.J. Rog, T.J. Nurmikko, T. Friede, and C.A. Young Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis Neurology 65 2005 812 819 (Pubitemid 41362120)
145. D.J. Rog, T.J. Nurmikko, and C.A. Young Oromucosal delta9- tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial Clinical Therapeutics 29 2007 2068 2079 (Pubitemid 350218115)
146. S. Rossi, R. Furlan, V.D. Chiara, L. Muzio, A. Musella, and C. Motta Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis Brain Behavior and Immunity 25 2011 1242 1248
147. S. Rossi, R. Furlan, V. De Chiara, A. Musella, T. Lo Giudice, and G. Mataluni Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis Neurobiology of Disease 36 2009 51 59
148. A. Rubio-Araiz, A. Arévalo-Martín, O. Gómez-Torres, B. Navarro-Galve, D. García-Ovejero, and P. Suetterlin The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation Molecular and Cellular Neuroscience 38 2008 374 380
149. E. Russo, and G.W. Guy A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol Medical Hypotheses 66 2006 234 246 (Pubitemid 41773895)
150. W.R. Schabitz, A. Giuffrida, C. Berger, A. Aschoff, M. Schwaninger, and S. Schwab Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study Stroke 33 2002 2112 2114 (Pubitemid 34840078)
151. T. Smith, A. Groom, B. Zhu, and L. Turski Autoimmune encephalomyelitis ameliorated by AMPA antagonists Nature Medicine 6 2000 62 66 (Pubitemid 30048527)
152. K.J. Smith, R. Kapoor, S.M. Hall, and M. Davies Electrically active axons degenerate when exposed to nitric oxide Annals of Neurology 49 2001 470 476 (Pubitemid 32281330)
153. D.T. Shakespeare, M. Boggild, and C. Young Anti-spasticity agents for multiple sclerosis Cochrane Database of Systematic Reviews 4 2003 CD001332
154. G.M. Simon, and B.F. Cravatt Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway Journal of Biological Chemistry 281 2006 26465 26472 (Pubitemid 44401855)
155. G.M. Simon, and B.F. Cravatt Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain Journal of Biological Chemistry 283 2008 9341 9349
156. J.E. Schlosburg, J.L. Blankman, J.Z. Long, D.K. Nomura, B. Pan, and S.G. Kinsey Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system Nature Neuroscience 13 2010 1113 1119
157. S. Sriram, and I. Steiner Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis Annals of Neurology 58 2005 939 945 (Pubitemid 41746884)
158. B. Szabo, M.J. Urbanski, T. Bisogno, V. Di Marzo, A. Mendiguren, and W.U. Baer Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol Journal of Physiology 577 2006 263 280 (Pubitemid 44698254)
159. P. Tagliaferro, A. Javier Ramos, E.S. Onaivi, S.G. Evrard, J. Lujilde, and A. Brusco Neuronal cytoskeleton and synaptic densities are altered after a chronic treatment with the cannabinoid receptor agonist WIN 55,212-2 Brain Research 1085 2006 163 176
160. A. Tanimura, M. Yamazaki, Y. Hashimotodani, M. Uchigashima, S. Kawata, and M. Abe The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission Neuron 65 2010 320 327
161. A. Thomas, G.L. Baillie, A.M. Phillips, R.K. Razdan, R.A. Ross, and R.G. Pertwee Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro British Journal of Pharmacology 150 2007 613 623 (Pubitemid 46355558)
162. K. Tsuboi, Y. Okamoto, N. Ikematsu, M. Inoue, Y. Shimizu, and T. Uyama Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways Biochimica et Biophysica Acta 1811 2011 565 577
163. N. Ueda, K. Tsuboi, T. Uyama, and T. Ohnishi Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol Biofactors 37 2011 1 7
164. S.A. Varvel, D.T. Bridgen, Q. Tao, B.F. Thomas, B.R. Martin, and A.H. Lichtman Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice Journal of Pharmacology and Experimental Therapeutics 314 2005 329 337 (Pubitemid 41058270)
165. S.A. Varvel, J.L. Wiley, R. Yang, D.T. Bridgen, K. Long, and A.H. Lichtman Interactions between THC and cannabidiol in mouse models of cannabinoid activity Psychopharmacology (Berlin) 186 2006 226 234 (Pubitemid 43727340)
166. D.T. Wade, P.M. Makela, H. House, C. Bateman, and P. Robson Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis Multiple Sclerosis 12 2006 639 645 (Pubitemid 46940638)
167. D.T. Wade, C. Collin, C. Stott, and P. Duncombe Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis Multiple Sclerosis 16 2010 707 714
168. Y. Wang The functional regulation of TRPV1 and its role in pain sensitization Neurochemical Research 33 2008 2008 2012
169. M. Webb, L. Luo, J.Y. Ma, and C.S. Tham Genetic deletion of fatty acid amide hydrolase results in improved long-term outcome in chronic autoimmune encephalitis Neuroscience Letters 439 2008 106 110
170. J.D. Wilkinson, B.J. Whalley, D. Baker, G. Pryce, A. Constanti, and S. Gibbons Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? Journal of Pharmacy and Pharmacology 55 2003 1687 1694 (Pubitemid 38054402)
171. R.I. Wilson, and R.A. Nicoll Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses Nature 410 2001 588 592 (Pubitemid 32267203)
172. R.I. Wilson, and R.A. Nicoll Endocannabinoid signaling in the brain Science 296 2002 678 682
173. A. Witting, L. Chen, E. Cudaback, A. Straiker, L. Walter, and B. Rickman Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection Proceedings of the National Academy of Sciences USA 103 2006 6362 6367
174. J.P. Zajicek, and V.I. Apostu Role of cannabinoids in multiple sclerosis CNS Drugs 25 2011 187 201
175. J. Zajicek, P. Fox, H. Sanders, D. Wright, J. Vickery, and A. Nunn Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial Lancet 362 2003 1517 1526 (Pubitemid 37410189)
176. J.P. Zajicek, H.P. Sanders, and D.E. Wright Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up Journal of Neurology, Neurosurgery, and Psychiatry 76 2005 1664 1669 (Pubitemid 41697631)
177. M. Zhang, B.R. Martin, M.W. Adler, R.J. Razdan, W. Kong, and D. Ganea Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke Journal of Neuroimmune Pharmacology 4 2009 249 259
178. HJ Zhu, JS Wang, JS Markowitz, JL Donovan, BB Gibson, and HA Gefroh Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana Journal of Pharmacology and Experimental Therapeutics 317 2006 850 857